High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
13.64B
+3.71%
1.926
-2.73%
13.60B
+2.77%
1.950
-14.47%
13.60B
-3.23%
2.100
-13.22%
Estimates Revision
The market is revising Upward the revenue expectations for Novartis AG (NVS) for FY2025, with the revenue forecasts being adjusted by 0.72% over the past three months. During the same period, the stock price has changed by 3.12%.
Revenue Estimates for FY2025
Revise Upward
+0.72%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.7%
In Past 3 Month
Stock Price
Go Up
+3.12%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast NVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVS is 129.00 USD with a low forecast of 118.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 132.430
Low
118.00
Averages
129.00
High
140.00
Current: 132.430
Low
118.00
Averages
129.00
High
140.00
Morgan Stanley
Overweight
maintain
$136 -> $143
2025-12-03
New
Reason
Morgan Stanley
Price Target
$136 -> $143
2025-12-03
New
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Novartis to $143 from $136 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
BofA
BofA
Neutral -> Buy
upgrade
2025-11-25
Reason
BofA
BofA
Price Target
2025-11-25
upgrade
Neutral -> Buy
Reason
BofA upgraded Novartis to Buy from Neutral with a price target of CHF 117, up from CHF 111. A long-standing overhang for investors has been the company's substantial patent cliffs into the end of the decade, with Cosentyx, Kesimpta and Kisqali, but the firm notes that the company already has several launches succeeding - including Pluvicto, Scemblix, and Leqvio - with new launches likely to add in Rhapsido and ianalumab.
Morgan Stanley
Equal Weight -> Overweight
upgrade
2025-10-31
Reason
Morgan Stanley
Price Target
2025-10-31
upgrade
Equal Weight -> Overweight
Reason
Morgan Stanley upgraded Novartis to Overweight from Equal Weight with a price target of CHF 110, up from CHF 108. The firm cites valuation for the upgrade following the recent shared selloff. Novartis is underdoing an improving portfolio mix into the upcoming Rhapsido launch, the analyst tells investors in a research note. Morgan Stanley expects the company's 2026 growth to be modest, but anticipates an acceleration from 2027.
Morgan Stanley
Equal Weight
maintain
2025-10-27
Reason
Morgan Stanley
Price Target
2025-10-27
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Novartis to CHF 108 from CHF 105 and keeps an Equal Weight rating on the shares.
Raymond James
Strong Buy -> Market Perform
downgrade
2025-10-27
Reason
Raymond James
Price Target
2025-10-27
downgrade
Strong Buy -> Market Perform
Reason
Raymond James downgraded Avidity Biosciences (RNA) to Market Perform from Strong Buy without a price target. Avidity Biosciences announced it has entered into an agreement to be acquired by Novartis (NVS). The firm believes the deal is "strategically sound," and Novartis is a "logical" buyer for Avidity given their presence in neuroscience and rare neuromuscular market, the analyst tells investors in a research note. The firm doesn't expect substantial regulatory risk surrounding this acquisition.
Jefferies
Michael Leuchten
Hold
initiated
CHF 110
2025-10-27
Reason
Jefferies
Michael Leuchten
Price Target
CHF 110
2025-10-27
initiated
Hold
Reason
Jefferies analyst Michael Leuchten assumed coverage of Novartis with a Hold rating and CHF 110 price target. While Novartis is facing meaningful patent expiries throughout the decade, there is "more replacement power than is appreciated by consensus," but this seems already reflected in the valuation, the analyst tells investors.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Novartis AG (NVS.N) is 0.00, compared to its 5-year average forward P/E of 12.82. For a more detailed relative valuation and DCF analysis to assess Novartis AG 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
12.82
Current PE
0.00
Overvalued PE
16.39
Undervalued PE
9.25
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
11.55
Current EV/EBITDA
11.83
Overvalued EV/EBITDA
12.37
Undervalued EV/EBITDA
10.73
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Overvalued
5Y Average PS
4.02
Current PS
4.71
Overvalued PS
4.38
Undervalued PS
3.66
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
NVS News & Events
Events Timeline
(ET)
2025-12-04
10:20:00
FDA Plans to Reduce Drug Approval Trials, Shares of Icon and Others Drop
2025-12-04
09:50:00
FDA Plans to Simplify Medical Product Approvals to One Clinical Study
2025-12-02 (ET)
2025-12-02
11:30:00
FDA Drug Regulator Richard Pazdur to Retire at Month-End
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/482461ee81b9c404180c748a9a29cad736c3dcf97a32a4b55c1fef8f79a2f125.png)
Preview
5.0
12-04Yahoo Finance2025 Intraocular Lens Market Competitor Analysis: Recent Developments, Strategies, Sustainability Benchmarks, Product Launches, Key Personnel, and Revenue Insights
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/7a04ca720b47048ab59d7d6ba0aa01a92eca6b5bd29eb0f95ce0516d58fcda21.png)
Preview
6.0
12-03CNBCKey Analyst Recommendations for Wednesday: Nvidia, Oracle, Apple, Broadcom, ASML, Marvell, Ralph Lauren, and Others
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/a5ba25cf73412fc8ef4e95ba097fc5a0eb6967fd03be2ce202c2e5cc166705e1.png)
Preview
9.0
12-02Barron'sJanux Therapeutics Shares Plunge 41% Despite 'Positive' Results from Cancer Drug Trial.
Sign Up For More News
People Also Watch
FAQ
What is Novartis AG (NVS) stock price today?
What is Novartis AG (NVS)'s business?
What is the price predicton of NVS Stock?
What is Novartis AG (NVS)'s revenue for the last quarter?
What is Novartis AG (NVS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Novartis AG (NVS)'s fundamentals?
How many employees does Novartis AG (NVS). have?